Drug Profile
Epoetin alfa biosimilar - Blau Farmaceutica
Alternative Names: Eritromax; recombinant-human-erythropoetin-alfa - BlauFarmaceutica; rHuEPO - BlauLatest Information Update: 10 Mar 2023
Price :
$50
*
At a glance
- Originator Blau Farmaceutica
- Class Antianaemics; Recombinant erythropoietins
- Mechanism of Action Cell stimulants; Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Anaemia
Most Recent Events
- 30 Jan 2023 Blau Farmaceutica plans a phase III trial for Chemotherapy induced anaemia (In children, In adolescents, Chemotherapy-induced) in May 2023 (IV) (NCT05704894)
- 14 May 2012 Launched for Anaemia in Brazil (IV, SC)